roslyn's library 78 articles Export

	Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study [My Copy] Journal of Immunological Methods, Vol. 345, No. 1-2. (30 June 2009), pp. 17-28. by Kelly M. Loyet, Rong Deng, Wei-Ching Liang, Yan Wu, Henry B. Lowman, Laura E. Deforge posted to neutralizing_antibodies neutralising nab ecl by roslyn on 2009-09-02 05:16:20 as along with 1 person wizblue
	A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum [My Copy] Journal of Immunological Methods, Vol. 345, No. 1-2. (30 June 2009), pp. 70-79. by Jenny Hu, Shalini Gupta, Steve J. Swanson, Yao Zhuang posted to neutralizing_antibodies nab ecl by roslyn on 2009-09-02 04:43:54 as
	IL-13 expression by blood T cells and not eosinophils is increased in asthma compared with non-asthmatic eosinophilic bronchitis [My Copy] BMC Pulmonary Medicine, Vol. 9, No. 1. (14 July 2009), 34. by Salman Siddiqui, Glenn Cruse, Susan Mckenna, et al.William Monteiro, Vijay Mistry, Andrew Wardlaw, Christopher Brightling posted to asthma by roslyn on 2009-07-23 08:14:37 as
	Antiphospholipid antibodies: Paradigm in transition [My Copy] Journal of Neuroinflammation, Vol. 6, No. 1. (20 January 2009), 3. by Lawrence Horstman, Wenche Jy, Carlos Bidot, et al.Yeon Ahn, Roger Kelley, Robert Zivadinov, Amir Maghzi, Masoud Etemadifar, Seyed Mousavi, Alireza Minagar posted to phospholipid rhdl by roslyn on 2009-07-22 06:18:44 as along with 1 person APSLuppa
	Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling. [My Copy] Current opinion in investigational drugs (London, England : 2000), Vol. 9, No. 11. (November 2008), pp. 1180-1184. by K. Blease posted to asthma by roslyn on 2009-07-17 06:09:54 as
	Is Sublingual Immunotherapy “Ready for Prime Time”? [My Copy] Chest, Vol. 133, No. 3. (March 2008), pp. 589-590. by Robert G. Townley posted to asthma by roslyn on 2009-07-16 08:56:22 as
	New targets for drug development in asthma. [My Copy] Lancet, Vol. 372, No. 9643. (20 September 2008), pp. 1073-1087. by I. M. Adcock, G. Caramori, K. F. Chung posted to asthma by roslyn on 2009-07-16 08:22:22 as along with 1 person Amazoness
	A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. [My Copy] The Journal of clinical investigation, Vol. 118, No. 4. (April 2008), pp. 1405-1416. by N. Müller, J. van den Brandt, F. Odoardi, et al.D. Tischner, J. Herath, A. Flügel, H. M. Reichardt posted to cd28 by roslyn on 2009-04-22 06:23:46 as
	Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. [My Copy] Human gene therapy, Vol. 17, No. 12. (December 2006), pp. 1177-1186. by M. L. Brantly, L. T. Spencer, M. Humphries, et al.T. J. Conlon, C. T. Spencer, A. Poirier, W. Garlington, D. Baker, S. Song, K. I. Berns, N. Muzyczka, R. O. Snyder, B. J. Byrne, T. R. Flotte posted to a1_antitrypsin by roslyn on 2009-03-12 11:21:14 as
	alpha1-Antitrypsin deficiency middle dot 2: Genetic aspects of alpha1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk [My Copy] Thorax, Vol. 59, No. 3. (1 March 2004), pp. 259-264. by D. L. Demeo, E. K. Silverman posted to no-tag by roslyn on 2009-03-08 05:03:05 as
	Autophagic disposal of the aggregation-prone protein that causes liver inflammation and carcinogenesis in α-1-antitrypsin deficiency [My Copy] Cell Death and Differentiation, Vol. aop, No. current. by D. H. Perlmutter posted to a1_antitrypsin by roslyn on 2009-02-28 03:46:16 as
	The role of autophagy in alpha-1-antitrypsin deficiency: a specific cellular response in genetic diseases associated with aggregation-prone proteins. [My Copy] Autophagy, Vol. 2, No. 4. (c 2006), pp. 258-263. by D. H. Perlmutter posted to a1_antitrypsin by roslyn on 2009-02-28 03:42:24 as
	Untangling the role of amyloid in atherosclerosis. [My Copy] Current opinion in lipidology, Vol. 17, No. 5. (October 2006), pp. 541-547. by G. J. Howlett, K. J. Moore posted to atherosclerosis by roslyn on 2009-02-28 03:35:46 as along with 1 person sahrazanetti
	Alpha1-antitrypsin deficiency: current perspective on research, diagnosis, and management. [My Copy] International journal of chronic obstructive pulmonary disease, Vol. 1, No. 2. (2006), pp. 151-160. by J. Stolk, N. Seersholm, N. Kalsheker posted to a1_antitrypsin by roslyn on 2009-02-28 03:30:34 as
	Aralast: an 1-protease inhibitor for the treatment of -antitrypsin deficiency [My Copy] Expert Opinion on Pharmacotherapy, Vol. 8, No. 15. (October 2007), pp. 2609-2614. by Mordwinkin, M. Nicholas, Louie, G. Stan posted to a1_antitrypsin by roslyn on 2009-02-28 03:29:25 as
	Hereditary alpha-1-antitrypsin deficiency and its clinical consequences [My Copy] Orphanet Journal of Rare Diseases, Vol. 3 (19 June 2008), 16. by Laura Fregonese, Jan Stolk posted to a1_antitrypsin by roslyn on 2009-02-28 03:12:22 as
	Liver Disease in Alpha 1-Antitrypsin Deficiency: A Review [My Copy] The American Journal of Gastroenterology, Vol. 103, No. 8. (August 2008), pp. 2136-2141. by Fairbanks, D. Kyrsten, Tavill, S. Anthony posted to a1_antitrypsin by roslyn on 2009-02-28 03:11:33 as
	Human interleukin 3: effects on normal and leukemic cells. [My Copy] Growth factors (Chur, Switzerland), Vol. 1, No. 2. (1989), pp. 101-114. by K. E. Barber, P. S. Crosier, K. J. Purdie, et al.J. M. Buchanan, J. A. Cattermole, J. D. Watson, S. Gillis posted to no-tag by roslyn on 2008-12-08 06:12:43 as
	Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. [My Copy] Journal of immunological methods, Vol. 293, No. 1-2. (October 2004), pp. 115-126. by X. Wei, S. J. Swanson, S. Gupta posted to neutralising validation by roslyn on 2008-11-25 03:49:22 as
	Key elements of bioanalytical method validation for macromolecules. [My Copy] The AAPS journal, Vol. 9, No. 2. (2007) by M. Kelley, B. DeSilva posted to validation by roslyn on 2008-11-25 03:42:08 as
	Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. [My Copy] Pharmaceutical research, Vol. 22, No. 9. (September 2005), pp. 1425-1431. by J. Smolec, B. DeSilva, W. Smith, et al.R. Weiner, M. Kelly, B. Lee, M. Khan, R. Tacey, H. Hill, A. Celniker, V. Shah, R. Bowsher, A. Mire-Sluis, J. W. Findlay, M. Saltarelli, V. Quarmby, D. Lansky, R. Dillard, M. Ullmann, S. Keller, H. T. Karnes posted to pharmacokinetics by roslyn on 2008-11-25 03:35:37 as
	"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. [My Copy] Journal of immunology (Baltimore, Md. : 1950), Vol. 179, No. 5. (1 September 2007), pp. 3325-3331. by R. Stebbings, L. Findlay, C. Edwards, et al.D. Eastwood, C. Bird, D. North, Y. Mistry, P. Dilger, E. Liefooghe, I. Cludts, B. Fox, G. Tarrant, J. Robinson, T. Meager, C. Dolman, S. J. Thorpe, A. Bristow, M. Wadhwa, R. Thorpe, S. Poole posted to general by roslyn on 2008-11-19 00:57:18 as
	Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. [My Copy] Journal of immunological methods, Vol. 278, No. 1-2. (July 2003), pp. 1-17. by M. Wadhwa, C. Bird, P. Dilger, R. Gaines-Das, R. Thorpe posted to immunogenicity by roslyn on 2008-11-19 00:56:44 as
	Use of biosensors to monitor the immune response. [My Copy] Developments in biologicals, Vol. 109 (2002), pp. 71-78. by S. J. Swanson, D. Mytych, J. Ferbas posted to biacore by roslyn on 2008-11-19 00:55:31 as
	A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs [My Copy] Nature Biotechnology, Vol. 25, No. 5. (04 May 2007), pp. 555-561. by Gopi Shankar, Charles Pendley, Kathryn E. Stein posted to immunogenicity by roslyn on 2008-11-19 00:49:16 as
	Scientific and regulatory considerations on the immunogenicity of biologics. [My Copy] Trends in biotechnology, Vol. 24, No. 6. (June 2006), pp. 274-280. by G. Shankar, E. Shores, C. Wagner, A. Mire-Sluis posted to immunogenicity by roslyn on 2008-11-19 00:48:33 as
	Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. [My Copy] Journal of immunological methods, Vol. 321, No. 1-2. (10 April 2007), pp. 1-18. by S. Gupta, S. R. Indelicato, V. Jethwa, et al.T. Kawabata, M. Kelley, A. R. Mire-Sluis, S. M. Richards, B. Rup, E. Shores, S. J. Swanson, E. Wakshull posted to immunogenicity neutralising validation by roslyn on 2008-11-19 00:26:30 as
	Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. [My Copy] Journal of pharmaceutical and biomedical analysis, Vol. 48, No. 5. (15 December 2008), pp. 1267-1281. by Gopi Shankar, Viswanath Devanarayan, Lakshmi Amaravadi, et al.Yu Chen C. Barrett, Ronald Bowsher, Deborah Finco-Kent, Michele Fiscella, Boris Gorovits, Susan Kirschner, Michael Moxness, Thomas Parish, Valerie Quarmby, Holly Smith, Wendell Smith, Linda A. Zuckerman, Eugen Koren posted to immunogenicity validation by roslyn on 2008-11-19 00:25:42 as
	Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. [My Copy] Journal of immunological methods, Vol. 333, No. 1-2. (20 April 2008), pp. 1-9. by E. Koren, H. W. Smith, E. Shores, et al.G. Shankar, D. Finco-Kent, B. Rup, Y. C. Barrett, V. Devanarayan, B. Gorovits, S. Gupta, T. Parish, V. Quarmby, M. Moxness, S. J. Swanson, G. Taniguchi, L. A. Zuckerman, C. C. Stebbins, A. Mire-Sluis posted to immunogenicity by roslyn on 2008-11-19 00:20:53 as along with 1 person sahrazanetti
	Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. [My Copy] Clinical chemistry, Vol. 51, No. 10. (October 2005), pp. 1983-1985. by M. Moxness, S. Tatarewicz, D. Weeraratne, et al.N. Murakami, D. Wullner, D. Mytych, V. Jawa, E. Koren, S. J. Swanson posted to ecl immunogenicity by roslyn on 2008-11-19 00:14:54 as
	Challenges with current technology for the detection, measurement and characterization of antibodies against biological therapeutics. [My Copy] Developments in biologicals, Vol. 109 (2002), pp. 59-69. by A. R. Mire-Sluis posted to immunogenicity by roslyn on 2008-11-19 00:12:56 as
	From characterization of antibodies to prediction of immunogenicity. [My Copy] Developments in biologicals, Vol. 109 (2002), pp. 87-95. by E. Koren posted to immunogenicity by roslyn on 2008-11-19 00:07:07 as
	Immunogenicity of engineered antibodies. [My Copy] Methods (San Diego, Calif.), Vol. 36, No. 1. (May 2005), pp. 3-10. by W. Y. Hwang, J. Foote posted to immunogenicity by roslyn on 2008-11-19 00:01:05 as
	Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO. [My Copy] Journal of immunological methods, Vol. 313, No. 1-2. (30 June 2006), pp. 176-182. by J. Gross, R. Moller, W. Henke, W. Hoesel posted to immunogenicity by roslyn on 2008-11-18 23:59:28 as
	Immunogenicity of therapeutic proteins: clinical implications and future prospects. [My Copy] Clinical therapeutics, Vol. 24, No. 11. (November 2002) by H. Schellekens posted to immunogenicity by roslyn on 2008-11-18 23:31:51 as along with 1 person sahrazanetti
	A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression. [My Copy] Journal of immunological methods, Vol. 316, No. 1-2. (20 October 2006), pp. 8-17. by Y. Yu, C. Piddington, D. Fitzpatrick, et al.B. Twomey, R. Xu, S. J. Swanson, S. Jing posted to neutralising by roslyn on 2008-11-18 23:17:23 as
	A non-radioactive method for detecting neutralizing antibodies against therapeutic proteins in serum. [My Copy] Journal of pharmaceutical and biomedical analysis, Vol. 45, No. 4. (30 November 2007), pp. 583-589. by I. Wala, S. J. Swanson, S. Jing posted to neutralising by roslyn on 2008-11-18 23:14:37 as
	Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. [My Copy] Pharmaceutical research, Vol. 24, No. 10. (October 2007), pp. 1962-1973. by C. T. Viswanathan, S. Bansal, B. Booth, et al.A. J. DeStefano, M. J. Rose, J. Sailstad, V. P. Shah, J. P. Skelly, P. G. Swann, R. Weiner posted to validation by roslyn on 2008-11-18 23:10:24 as
	Antibodies against erythropoietin and other protein-based therapeutics: an overview. [My Copy] Annals of the New York Academy of Sciences, Vol. 1050 (June 2005), pp. 257-265. by A. Kromminga, H. Schellekens posted to immunogenicity review by roslyn on 2008-11-18 23:01:55 as
	Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. [My Copy] Rheumatology (Oxford, England), Vol. 46, No. 12. (December 2007), pp. 1828-1834. by M. Svenson, P. Geborek, T. Saxne, K. Bendtzen posted to immunogenicity pharmacokinetics by roslyn on 2008-11-18 22:42:41 as along with 1 person sahrazanetti
	Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. [My Copy] Arthritis and rheumatism, Vol. 54, No. 12. (December 2006), pp. 3782-3789. by K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M. C. Kapetanovic, T. Saxne posted to immunogenicity by roslyn on 2008-11-18 22:41:49 as
	A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs [My Copy] International Immunopharmacology, Vol. 8, No. 3. (March 2008), pp. 401-413. by J. Davda, M. Jain, S. Batra, P. Gwilt, D. Robinson posted to pbpk by roslyn on 2008-11-10 14:14:26 as
	Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. [My Copy] Cancer research, Vol. 55, No. 20. (15 October 1995), pp. 4611-4622. by L. T. Baxter, H. Zhu, D. G. Mackensen, W. F. Butler, R. K. Jain posted to species by roslyn on 2008-11-10 11:15:25 as
	Species similarities and differences in pharmacokinetics. [My Copy] Drug metabolism and disposition: the biological fate of chemicals, Vol. 23, No. 10. (October 1995), pp. 1008-1021. by J. H. Lin posted to major_ass pharmacokinetics species by roslyn on 2008-11-08 02:26:12 as along with 1 person medhakhanna
	Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. [My Copy] Journal of clinical pharmacology, Vol. 41, No. 11. (November 2001), pp. 1206-1214. by J. A. Dowell, J. Korth-Bradley, H. Liu, S. P. King, M. S. Berger posted to antibody major_ass pharmacokinetics by roslyn on 2008-11-07 01:32:53 as
	Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. [My Copy] Journal of clinical pharmacology, Vol. 44, No. 8. (August 2004), pp. 873-880. by M. Buckwalter, J. A. Dowell, J. Korth-Bradley, B. Gorovits, P. R. Mayer posted to antibody major_ass pharmacokinetics by roslyn on 2008-11-07 01:32:23 as
	Role of pharmacokinetics and metabolism in drug discovery and development. [My Copy] Pharmacological reviews, Vol. 49, No. 4. (December 1997), pp. 403-449. by J. H. Lin, A. Y. Lu posted to pharmacokinetics by roslyn on 2008-11-06 23:43:48 as along with 1 person sahrazanetti
	How to predict and prevent the immunogenicity of therapeutic proteins. [My Copy] Biotechnology annual review, Vol. 14 (2008), pp. 191-202. by H. Schellekens posted to immunogenicity by roslyn on 2008-11-06 23:32:16 as along with 1 person sahrazanetti
	Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates [My Copy] Br J Pharmacol, Vol. 148, No. 8. (10 July 2006), pp. 1116-1123. by Sean K. Kelley, Thomas Gelzleichter, Dong Xie, et al.Wyne P. Lee, Walter C. Darbonne, Ferhan Qureshi, Kim Kissler, Ezogelin Oflazoglu, Iqbal S. Grewal posted to no-tag by roslyn on 2008-11-06 23:26:02 as
	Drug interaction studies of therapeutic proteins or monoclonal antibodies. [My Copy] Journal of clinical pharmacology, Vol. 47, No. 12. (December 2007), pp. 1540-1554. by I. Mahmood, M. D. Green posted to pharmacokinetics by roslyn on 2008-11-06 23:14:23 as along with 1 person sahrazanetti

Note: You may cite this page as: http://www.citeulike.org/user/roslyn

Result page: 1 2 Next

immunogenicity	20
pharmacokinetics	15
antibody	10
a1_antitrypsin	7
ass4	7
neutralising	6
validation	5
asthma	4
ass5	3
ecl	3
major_ass	3
interaction	2
nab	2
neutralizing_antibodies	2
species	2
acid-dissociation	1
atherosclerosis	1
biacore	1
cd28	1
cut-off	1
elisa	1
general	1
il3	1
liver	1
pbpk	1
phospholipid	1
review	1
rhdl	1
tox	1

roslyn's library 78 articles Export

roslyn's tags